6 results on '"Muffatti, Francesca"'
Search Results
2. A Single-center Prospective Observational Study Investigating the Accuracy of Preoperative Diagnostic Procedures in the Assessment of Lymph Node Metastases in Nonfunctioning Pancreatic Neuroendocrine Tumors
- Author
-
Stefano Partelli, Francesca Muffatti, Valentina Andreasi, Fabio Giannone, Gemma Rossi, Diego Palumbo, Paola Mapelli, Marco Schiavo Lena, Paolo Giorgio Arcidiacono, Francesco De Cobelli, Maria Picchio, Claudio Doglioni, Massimo Falconi, Partelli, Stefano, Muffatti, Francesca, Andreasi, Valentina, Giannone, Fabio, Rossi, Gemma, Palumbo, Diego, Mapelli, Paola, Schiavo Lena, Marco, Arcidiacono, Paolo Giorgio, De Cobelli, Francesco, Picchio, Maria, Doglioni, Claudio, and Falconi, Massimo
- Subjects
Pancreatic Neoplasms ,Neuroendocrine Tumors ,Lymphatic Metastasis ,Positron Emission Tomography Computed Tomography ,Positron-Emission Tomography ,Humans ,Gallium Radioisotopes ,Surgery ,Prospective Studies - Abstract
To determine the accuracy of preoperative imaging, including contrast-enhanced computed tomography (CE-CT), endoscopic ultrasound (EUS), and 68 Gallium-DOTATOC positron emission tomography ( 68 Ga-DOTATOC PET), in identifying nodal metastases (N+) in sporadic nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).An accurate preoperative identification of N+ in NF-PanNETs is critical for surgical planning. The accuracy of different imaging techniques in detecting lymph node (LN) metastases in NF-PanNETs has been poorly investigated.All consecutive patients undergoing surgery for sporadic NF-PanNETs (2018-2021) were enrolled in a prospective study (DETECTYON; NCT03918759). The accuracy of preoperative imaging techniques in detecting N+ was assessed through sensitivity, specificity positive and negative predictive values.Overall, 100 patients with NF-PanNETs underwent CE-CT, EUS, and 68 Ga-DOTATOC PET before pancreatic resection. LN metastases were found in 42 cases (42%). Sensitivity, specificity, positive predictive value, and negative predictive value of different imaging techniques were 26%, 95%, 79%, 64% for CE-CT, 19%, 98%, 89%, 63% for EUS, and 12%, 95%, 63%, 60% for 68 Ga-DOTATOC PET, respectively. Radiologic tumor size4 cm and the presence of radiologic N+ at ≥1 imaging were independent predictors of N+ at pathology. The identification of N+ at ≥1 imaging technique was associated with a higher number of positive LNs compared with negative imaging (4 vs 2) ( P =0.012).CE-CT, EUS, and 68 Ga-DOTATOC PET are poorly sensitive in predicting nodal status in NF-PanNETs despite a high specificity.
- Published
- 2022
- Full Text
- View/download PDF
3. How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery
- Author
-
Francesca, Fermi, Valentina, Andreasi, Francesca, Muffatti, Stefano, Crippa, Domenico, Tamburrino, Stefano, Partelli, Massimo, Falconi, Fermi, Francesca, Andreasi, Valentina, Muffatti, Francesca, Crippa, Stefano, Tamburrino, Domenico, Partelli, Stefano, and Falconi, Massimo
- Subjects
Active surveillance ,Fitness for surgery ,Prognosis ,Functional outcomes ,Pancreatic Neoplasms ,Neuroendocrine Tumors ,Oncology ,Endoscopic resection ,GEP-NENs ,Stomach Neoplasms ,Neuroendocrine neoplasms ,Surgical indications ,Intestinal Neoplasms ,Humans ,Oncological risk ,Surgery ,Selection for surgery ,Surgical risk ,Gastrointestinal Neoplasms - Abstract
Purpose of Review The aim of this review was to discuss how to select patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) for surgery. Recent Findings Surgical resection represents the mainstay for the curative treatment of GEP-NENs. Conservative strategies, such as endoscopic resection and active surveillance, have been recently advocated for the management of patients with small and asymptomatic GEP-NENs. On the other hand, patients with GEP-NENs showing features of aggressiveness should be managed by surgical resection with lymphadenectomy, when the surgical risk is considered acceptable. An accurate selection is important also in the setting of advanced disease, where surgery can provide a survival benefit in the context of a multimodal treatment strategy. Surgical and oncological risk should be always assessed in order to define indications for surgery in patients with GEP-NENs. Given the variety of available treatment options, surgical indication should be always shared with a dedicated multidisciplinary team.
- Published
- 2022
- Full Text
- View/download PDF
4. Preoperative assessment of microvessel density in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs)
- Author
-
Anna Battistella, Stefano Partelli, Valentina Andreasi, Ilaria Marinoni, Diego Palumbo, Matteo Tacelli, Marco Schiavo Lena, Francesca Muffatti, Junaid Mushtaq, Gabriele Capurso, Paolo Giorgio Arcidiacono, Francesco De Cobelli, Claudio Doglioni, Aurel Perren, Massimo Falconi, Battistella, Anna, Partelli, Stefano, Andreasi, Valentina, Marinoni, Ilaria, Palumbo, Diego, Tacelli, Matteo, Lena, Marco Schiavo, Muffatti, Francesca, Mushtaq, Junaid, Capurso, Gabriele, Arcidiacono, Paolo Giorgio, De Cobelli, Francesco, Doglioni, Claudio, Perren, Aurel, and Falconi, Massimo
- Subjects
Pancreatic Neoplasms ,Neuroendocrine Tumors ,Hepatology ,Endocrinology, Diabetes and Metabolism ,Gastroenterology ,570 Life sciences ,biology ,Humans ,Surgery ,610 Medicine & health ,Tomography, X-Ray Computed ,Microvascular Density ,Retrospective Studies - Abstract
BACKGROUND Hypervascularization is a typical feature of pancreatic neuroendocrine tumors, and it frequently allows their recognition at imaging studies. However, the density of microvessels in pancreatic neuroendocrine tumors changes according to their biological behavior, and a low microvessel density is associated with higher disease aggressiveness. The primary aim was to investigate the relationship between microvessel density and aggressiveness of nonfunctioning pancreatic neuroendocrine tumors. The secondary aim was to evaluate the ability of contrast-enhanced computed tomography and contrast-enhanced endoscopic ultrasound in predicting tumor microvessel density. METHODS The patients who underwent surgery for nonfunctioning pancreatic neuroendocrine tumors (n = 66) with an available preoperative contrast-enhanced computed tomography (n = 39) and/or contrast-enhanced endoscopic ultrasound (n = 37) performed at San Raffaele Hospital (2016-2020) were included. The tumor vascularization was assessed by CD-34 staining, contrast-enhanced computed tomography, and contrast-enhanced endoscopic ultrasound. Median microvessel density (165 microvessels/mm2) was chosen as the cutoff to define low microvessel density and high microvessel density. RESULTS The patients with a low microvessel density showed a significantly higher frequency of nodal metastases (P = .026), G2-G3 tumors (P = .022), and death domain-associated protein/α-thalassemia/mental retardation syndrome X-linked loss (P = .011) compared to patients with high microvessel density. The contrast-enhanced computed tomography tumor density in the arterial phase was significantly higher in patients with high microvessel density compared to those with low microvessel density (P = .016). The patients with a low microvessel density showed a significantly higher frequency of contrast-enhanced endoscopic ultrasound arterial hypoenhancement (P = .042) and late washout (P = .034). Contrast-enhanced computed tomography arterial hypoenhancement (P = .007) and contrast-enhanced endoscopic ultrasound late washout (P = .048) independently predicted a low microvessel density in the patients who underwent contrast-enhanced computed tomography and contrast-enhanced endoscopic ultrasound, respectively. CONCLUSION A low microvessel density represents a marker of aggressiveness in the patients with nonfunctioning pancreatic neuroendocrine tumors. Contrast-enhanced computed tomography and contrast-enhanced endoscopic ultrasound are reliable and easily available tools for preoperative assessment of microvessel density.
- Published
- 2022
- Full Text
- View/download PDF
5. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial
- Author
-
Stefano Partelli, Sara Massironi, Alessandro Zerbi, Patricia Niccoli, Wooil Kwon, Luca Landoni, Francesco Panzuto, Ales Tomazic, Alberto Bongiovanni, Gregory Kaltsas, Alain Sauvanet, Emilio Bertani, Vincenzo Mazzaferro, Martyn Caplin, Thomas Armstrong, Martin O Weickert, John Ramage, Eva Segelov, Giovanni Butturini, Stefan Staettner, Mauro Cives, Andrea Frilling, Carol Anne Moulton, Jin He, Florian Boesch, Andreas Selberheer, Orit Twito, Antonio Castaldi, Claudio G De Angelis, Sebastien Gaujoux, Katharina Holzer, Colin H Wilson, Hussein Almeamar, Emanuel Vigia, Francesca Muffatti, Martina Lucà, Andrea Lania, Jacques Ewald, Hongbeom Kim, Roberto Salvia, Maria Rinzivillo, Alojz Smid, Andrea Gardini, Marina Tsoli, Olivia Hentic, Samuele Colombo, Davide Citterio, Christos Toumpanakis, Emma Ramsey, Harpal S Randeva, Ray Srirajaskanthan, Daniel Croagh, Paolo Regi, Silvia Gasteiger, Pietro Invernizzi, Cristina Ridolfi, Marc Giovannini, Jin-Young Jang, Claudio Bassi, Massimo Falconi, Partelli, Stefano, Massironi, Sara, Zerbi, Alessandro, Niccoli, Patricia, Kwon, Wooil, Landoni, Luca, Panzuto, Francesco, Tomazic, Ale, Bongiovanni, Alberto, Kaltsas, Gregory, Sauvanet, Alain, Bertani, Emilio, Mazzaferro, Vincenzo, Caplin, Martyn, Armstrong, Thoma, Weickert, Martin O, Ramage, John, Segelov, Eva, Butturini, Giovanni, Staettner, Stefan, Cives, Mauro, Frilling, Andrea, Moulton, Carol Anne, He, Jin, Boesch, Florian, Selberheer, Andrea, Twito, Orit, Castaldi, Antonio, De Angelis, Claudio G, Gaujoux, Sebastien, Holzer, Katharina, Wilson, Colin H, Almeamar, Hussein, Vigia, Emanuel, Muffatti, Francesca, Lucà, Martina, Lania, Andrea, Ewald, Jacque, Kim, Hongbeom, Salvia, Roberto, Rinzivillo, Maria, Smid, Alojz, Gardini, Andrea, Tsoli, Marina, Hentic, Olivia, Colombo, Samuele, Citterio, Davide, Toumpanakis, Christo, Ramsey, Emma, Randeva, Harpal S, Srirajaskanthan, Ray, Croagh, Daniel, Regi, Paolo, Gasteiger, Silvia, Invernizzi, Pietro, Ridolfi, Cristina, Giovannini, Marc, Jang, Jin Young, Bassi, Claudio, and Falconi, Massimo
- Subjects
asymptomatic pancreatic neuroendocrine neoplasms ,Pancreatic surgery ,asymptomatic pancreatic neuroendocrine neoplasms, Pancreatic neoplasm, Pancreatic surgery ,pancreatic endocrine tumors ,surgery ,management ,prognosis ,Pancreatic Neoplasms ,Settore MED/18 - Chirurgia Generale ,Neuroendocrine Tumors ,Pancreatectomy ,Humans ,Surgery ,Prospective Studies ,Pancreatic neoplasm - Published
- 2022
6. Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET)
- Author
-
Massimo Falconi, Stefano Partelli, Valentina Andreasi, Francesca Muffatti, Barbara Colombo, Angelo Corti, Marco F. Manzoni, Andreasi, Valentina, Partelli, Stefano, Manzoni, Marco, Muffatti, Francesca, Colombo, Barbara, Corti, Angelo, and Falconi, Massimo
- Subjects
Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Neuroendocrine tumors ,Sensitivity and Specificity ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Pancreatic neuroendocrine tumor ,Internal medicine ,Biomarkers, Tumor ,Humans ,Medicine ,Small Intestinal NET ,Pathological ,Retrospective Studies ,Hepatology ,Plasma samples ,biology ,business.industry ,Nodal metastasis ,Vasostatin-1 ,Chromogranin A ,Biomarker ,Plasma levels ,Middle Aged ,medicine.disease ,Peptide Fragments ,Pancreatic Neoplasms ,Neuroendocrine Tumors ,030220 oncology & carcinogenesis ,biology.protein ,Biomarker (medicine) ,Female ,030211 gastroenterology & hepatology ,business - Abstract
Background A reliable and accessible biomarker for nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET) is currently unavailable. Chromogranin A (CgA) represents the best-described neuroendocrine biomarker, but its accuracy is low. Vasostatin-1 (VS-1), a fragment derived from the cleavage of CgA, was recently investigated and found to be more accurate as tumor biomarker in a cohort of patients affected by mainly metastatic small intestinal NET. Methods Patients submitted to surgery for sporadic localized NF-PanNET at San Raffaele Hospital were included. Preoperative plasma samples were prospectively collected. Circulating levels of total-CgA and VS-1 were retrospectively investigated by sandwich Enzyme-Linked ImmunoSorbent Assays. Results Overall, 50 patients were included. VS-1 value (P=0.0001) was the only preoperatively retrievable factor independently associated with NF-PanNET size. No significant correlation between CgA and tumor diameter was found (P = 0.057). A VS-1 value of 0.39 nM was identified as the optimal VS-1 cut-off accurately associated with NF-PanNET larger than 4 cm. Patients with VS-1 > 0.39 nM had a significantly higher frequency of microvascular invasion (P = 0.005) and nodal metastasis (P = 0.027). Median VS-1 plasma level was significantly higher in the presence of microvascular invasion (P = 0.001) and nodal metastasis (P = 0.012). PPI assumption significantly increased total-CgA levels, but not those of VS-1 (P = 0.111). Conclusions In localized, non-metastatic NF-PanNET, VS-1 is strongly associated to tumor dimension and its plasma levels are significantly higher in the presence of microvascular invasion and nodal metastases; moreover, VS-1 value is not affected by the PPI use.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.